Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of treatment for refractory focal onset seizures, associated with tuberous sclerosis complex, for ages 2 years and above.

Document

Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)

Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)

  • 21 pages